MondayJul 24, 2017 12:06 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Aims at Future of Cannabinoid Compound Treatment

Specializing in novel cannabinoid drug therapies, InMed Pharmaceuticals is well-poised for cannabinoid research and development of new treatments Glaucoma and skin disease pharmaceuticals now in development have an estimated $7.6 billion potential market InMed Pharmaceutical’s chief medical officer helped $3 billion GW Pharmaceuticals develop one of the first cannabis-based drugs With its proprietary bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is well-positioned to target the future of cannabinoid pharmaceutical compounds. InMed is a pre-clinical stage biopharmaceutical company specializing in the development of novel therapies through research and development of the…

Continue Reading

TuesdayJul 18, 2017 2:39 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Well-positioned For Expanding Canadian Cannabinoid Market

Lexaria Bioscience Corp. well-positioned for growth in expanding Canadian cannabinoid market Canadian market for cannabis extracts and oils expected to top C$1.6 billion by 2020 Company’s patented technology infuses organically sourced hemp oil into molecules of other substances such as lipids, the basis of the human endocannabinoid system Patented technology enables better-tasting hemp oil-infused gourmet food products with improved bioavailability of cannabinoids Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth in the emerging Canadian cannabinoid market. Lexaria is an innovative revenue-generating company developing and out-licensing proprietary technology for delivering bioactive compounds including cannabinoids. With full legalization expected…

Continue Reading

WednesdayJul 12, 2017 12:48 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is “One to Watch”

Revenue-generating biosciences company focused on improving the delivery of bioactive compounds through gourmet foods Proprietary technology shown to enhance the bioavailability of orally ingested cannabinoids while improving the taste Actively developing and selling hemp oil-based gourmet food products through consumer brands ViPova™ and Lexaria Energy Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a…

Continue Reading

ThursdayJul 06, 2017 2:55 pm

Invictus MD (TSX.V: IMH) (OTC: IVITF) Poised to Have First-Mover Advantage in Canada’s Legal Cannabis Market

One of few Canadian cannabis companies to declare dividends Poised for first-mover advantage in Canada’s legal marijuana market 250 acres of cultivation space spanning from Alberta to Ontario Retail sales in Canada’s recreational marijuana market could climb to $6.0 billion by 2021, according to Deloitte Canadian, and Invictus MD Strategies Corp. (TSX.V: IMH) (OTC: IVITF) is strategically positioned to grow right alongside this burgeoning market and gain first-mover advantage as soon as Canada’s cannabis market is freed up by the necessary legislative regulations. Founded in Vancouver, Canada, Invictus MD is a cannabis company that is dedicated to offering high-quality, regulated…

Continue Reading

WednesdayJul 05, 2017 12:45 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Focused on the Science of Cannabinoids

Science-based cannabinoid pharmaceuticals are big market winners InMed Pharmaceuticals is developing two potential blockbuster drugs IMLFF has innovative and disruptive market advantages The market is rife with hype, pretenders and wannabes in the booming cannabis markets. In the rush to find the next hot cannabis stock, investors often overlook the real value in long-term scientific applications, and, after the heady hoopla of once-illicit marijuana dies down, those that chose science will be the ultimate winners. The medicinal and scientific applications of the 90 individual cannabinoid drugs found in cannabis are where the real value lies. Look no further than GW…

Continue Reading

WednesdayJul 05, 2017 8:54 am

Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) is a Technology Disruptor for Edible Cannabinoids

First mover in plant-to-bloodstream niche Proprietary technology improving bioavailability of orally ingested cannabinoids Two distinct consumer product brands: ViPova™ and Lexaria Energy With the recreational market set for legalization on July 1, 2018, Canada’s cannabis industry is experiencing a high that is catalyzing innovation in the biosciences sector. Pioneering biopharmaceutical companies there and in other developed countries are working to develop a variety of healthful products based on their research into cannabinoids. As a result, investment capital flow to “plant-to-bloodstream” companies is expected to swell just as it has been doing for “seed-to-plant” companies for some time, and innovative British…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977